BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 35105853)

  • 21. Valtrate, an iridoid compound in Valeriana, elicits anti-glioblastoma activity through inhibition of the PDGFRA/MEK/ERK signaling pathway.
    Liu X; Hu Y; Xue Z; Zhang X; Liu X; Liu G; Wen M; Chen A; Huang B; Li X; Yang N; Wang J
    J Transl Med; 2023 Feb; 21(1):147. PubMed ID: 36829235
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased expression of EphA2 correlates with adverse outcome in primary and recurrent glioblastoma multiforme patients.
    Wang LF; Fokas E; Bieker M; Rose F; Rexin P; Zhu Y; Pagenstecher A; Engenhart-Cabillic R; An HX
    Oncol Rep; 2008 Jan; 19(1):151-6. PubMed ID: 18097589
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Overexpression of PDGFA and its receptor during carcinogenesis of Opisthorchis viverrini-associated cholangiocarcinoma.
    Boonjaraspinyo S; Wu Z; Boonmars T; Kaewkes S; Loilome W; Sithithaworn P; Nagano I; Takahashi Y; Yongvanit P; Bhudhisawasdi V
    Parasitol Int; 2012 Mar; 61(1):145-50. PubMed ID: 21777692
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Soluble monomeric EphrinA1 is released from tumor cells and is a functional ligand for the EphA2 receptor.
    Wykosky J; Palma E; Gibo DM; Ringler S; Turner CP; Debinski W
    Oncogene; 2008 Dec; 27(58):7260-73. PubMed ID: 18794797
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ERBB3, IGF1R, and TGFBR2 expression correlate with PDGFR expression in glioblastoma and participate in PDGFR inhibitor resistance of glioblastoma cells.
    Song K; Yuan Y; Lin Y; Wang YX; Zhou J; Gai QJ; Zhang L; Mao M; Yao XX; Qin Y; Lu HM; Zhang X; Cui YH; Bian XW; Zhang X; Wang Y
    Am J Cancer Res; 2018; 8(5):792-809. PubMed ID: 29888103
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bioinformatic analyses reveal a distinct Notch activation induced by STAT3 phosphorylation in the mesenchymal subtype of glioblastoma.
    Cheng W; Zhang C; Ren X; Jiang Y; Han S; Liu Y; Cai J; Li M; Wang K; Liu Y; Hu H; Li Q; Yang P; Bao Z; Wu A
    J Neurosurg; 2017 Jan; 126(1):249-259. PubMed ID: 26967788
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Overexpression of platelet-derived growth factor receptor alpha promotes tumor progression and indicates poor prognosis in hepatocellular carcinoma.
    Wei T; Zhang LN; Lv Y; Ma XY; Zhi L; Liu C; Ma F; Zhang XF
    Oncotarget; 2014 Nov; 5(21):10307-17. PubMed ID: 25333264
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Platelet-derived growth factor in glioblastoma-driver or biomarker?
    Westermark B
    Ups J Med Sci; 2014 Nov; 119(4):298-305. PubMed ID: 25342206
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Platelet-Derived Growth Factor Receptor-α Regulates Proliferation of Gastrointestinal Stromal Tumor Cells With Mutations in KIT by Stabilizing ETV1.
    Hayashi Y; Bardsley MR; Toyomasu Y; Milosavljevic S; Gajdos GB; Choi KM; Reid-Lombardo KM; Kendrick ML; Bingener-Casey J; Tang CM; Sicklick JK; Gibbons SJ; Farrugia G; Taguchi T; Gupta A; Rubin BP; Fletcher JA; Ramachandran A; Ordog T
    Gastroenterology; 2015 Aug; 149(2):420-32.e16. PubMed ID: 25865047
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ZWINT: A potential therapeutic biomarker in patients with glioblastoma correlates with cell proliferation and invasion.
    Yang L; Han N; Zhang X; Zhou Y; Chen R; Zhang M
    Oncol Rep; 2020 Jun; 43(6):1831-1844. PubMed ID: 32323832
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.
    Stangeland B; Mughal AA; Grieg Z; Sandberg CJ; Joel M; Nygård S; Meling T; Murrell W; Vik Mo EO; Langmoen IA
    Oncotarget; 2015 Sep; 6(28):26192-215. PubMed ID: 26295306
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Distinct phenotypic differences associated with differential amplification of receptor tyrosine kinase genes at 4q12 in glioblastoma.
    Burford A; Little SE; Jury A; Popov S; Laxton R; Doey L; Al-Sarraj S; Jürgensmeier JM; Jones C
    PLoS One; 2013; 8(8):e71777. PubMed ID: 23990986
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cotargeting Ephrin Receptor Tyrosine Kinases A2 and A3 in Cancer Stem Cells Reduces Growth of Recurrent Glioblastoma.
    Qazi MA; Vora P; Venugopal C; Adams J; Singh M; Hu A; Gorelik M; Subapanditha MK; Savage N; Yang J; Chokshi C; London M; Gont A; Bobrowski D; Grinshtein N; Brown KR; Murty NK; Nilvebrant J; Kaplan D; Moffat J; Sidhu S; Singh SK
    Cancer Res; 2018 Sep; 78(17):5023-5037. PubMed ID: 29945963
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A cell-autonomous positive-signaling circuit associated with the PDGF-NO-ID4-regulatory axis in glioblastoma cells.
    Eun K; Jeon HM; Kim SO; Choi SH; Lee SY; Jin X; Kim SC; Kim H
    Biochem Biophys Res Commun; 2017 Apr; 486(2):564-570. PubMed ID: 28327358
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma.
    Kubo T; Piperdi S; Rosenblum J; Antonescu CR; Chen W; Kim HS; Huvos AG; Sowers R; Meyers PA; Healey JH; Gorlick R
    Cancer; 2008 May; 112(10):2119-29. PubMed ID: 18338812
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ligand-dependent platelet-derived growth factor receptor (PDGFR)-alpha activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors.
    McDermott U; Ames RY; Iafrate AJ; Maheswaran S; Stubbs H; Greninger P; McCutcheon K; Milano R; Tam A; Lee DY; Lucien L; Brannigan BW; Ulkus LE; Ma XJ; Erlander MG; Haber DA; Sharma SV; Settleman J
    Cancer Res; 2009 May; 69(9):3937-46. PubMed ID: 19366796
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PDGFRα depletion attenuates glioblastoma stem cells features by modulation of STAT3, RB1 and multiple oncogenic signals.
    Cenciarelli C; Marei HE; Felsani A; Casalbore P; Sica G; Puglisi MA; Cameron AJ; Olivi A; Mangiola A
    Oncotarget; 2016 Aug; 7(33):53047-53063. PubMed ID: 27344175
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overexpression of Platelet-Derived Growth Factor and Its Receptor Are Correlated with Oral Tumorigenesis and Poor Prognosis in Oral Squamous Cell Carcinoma.
    Lin LH; Lin JS; Yang CC; Cheng HW; Chang KW; Liu CJ
    Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32235327
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Induction of nuclear protein-1 by thyroid hormone enhances platelet-derived growth factor A mediated angiogenesis in liver cancer.
    Chen CY; Wu SM; Lin YH; Chi HC; Lin SL; Yeh CT; Chuang WY; Lin KH
    Theranostics; 2019; 9(8):2361-2379. PubMed ID: 31149049
    [No Abstract]   [Full Text] [Related]  

  • 40. EphA2 is a key effector of the MEK/ERK/RSK pathway regulating glioblastoma cell proliferation.
    Hamaoka Y; Negishi M; Katoh H
    Cell Signal; 2016 Aug; 28(8):937-45. PubMed ID: 27132626
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.